RxDoctor Payments Data

Charles Schultz, MD

Neurology · Ann Arbor, MINPI 1386693653

Payments from drug & device makers

$9,228in general payments, 2019–2025

Across 103 payments — averaging $89.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AbbVie$2K
  • Amgen$1K
  • Lilly USA, LLC$871
  • Teva Pharmaceuticals USA, Inc.$558
  • UCB, Inc.$387
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$2,80030%
  • Food & beverage$6,42870%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,228 in reported general payments places this provider in the 70th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$26,861
Medicare patients
90
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm315$237,109
Aimovig AutoinjectorErenumab-Aooe297$233,664
Nurtec OdtRimegepant Sulfate123$193,916
QuliptaAtogepant104$111,555
UbrelvyUbrogepant51$80,348
Ajovy AutoinjectorFremanezumab-Vfrm45$32,254
ZavzpretZavegepant Hcl27$29,628
Emgality SyringeGalcanezumab-Gnlm18$29,498
Sumatriptan Succinate150$9,658
ReyvowLasmiditan Succinate12$5,504
RizatriptanRizatriptan Benzoate206$3,960
Frovatriptan Succinate14$3,891
Memantine Hcl73$3,840
Sumatriptan12$3,721
Naratriptan Hcl130$2,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$2,105$191,903155 claims
Lilly USA, LLCReyvow$871$5,50412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 652 neurology providers in Michigan.

Other neurology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →